- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05687825
Risk Factors for Clinically Relevant Postoperative Pancreatic Fistula
July 25, 2023 updated by: Mohammed Ahmed Omar, MD, South Valley University
Operative Risk Factors for Clinically Relevant Postoperative Pancreatic Fistula After Pancreaticoduodenectomy: A Prospective Multicenter Cohort Study
For periampullary and pancreatic head disorders, pancreaticoduodenectomy (PD) is the standard treatment.
However, PD is technically demanding and has high morbidity and mortality rates.
The most significant and life-threatening complication of PD is postoperative pancreatic fistula (POPF), with reported rates of 5 to 70% for total POPF and 10 to 45% for clinically relevant (CR-POPF).
Operative risk variables for CR-POPF after PD were investigated in this study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
For periampullary and pancreatic head disorders, pancreaticoduodenectomy (PD) is the standard treatment.
However, PD is technically demanding and has high morbidity and mortality rates.
The most significant and life-threatening complication of PD is postoperative pancreatic fistula (POPF), with reported rates of 5 to 70% for total POPF and 10 to 45% for clinically relevant (CR-POPF).
Operative risk variables for CR-POPF after PD were investigated in this study.
Study Type
Observational
Enrollment (Actual)
107
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Qena faculty of Medicine, South Valley University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
all consecutive patients who were treated with a pancreaticoduodenectomy
Description
Inclusion Criteria:
- Patients with resectable distal CBD carcinoma, periampullary carcinoma, duodenal carcinoma, and carcinoma of the head of the pancreas.
- American Society of Anesthesiologists (ASA) scores I & II.
- Patients aged > 20 years.
- Agreement to complete the study.
Exclusion Criteria:
- Patients with benign disease, trauma, and receive neoadjuvant therapy.
- double primary cancers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Clinically relevant postoperative pancreatic fistula
patients who developed clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
|
Pancreaticoduodenectomy operation
|
|
No clinically relevant postoperative pancreatic fistula
patients who did not develop clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
|
Pancreaticoduodenectomy operation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
clinically relevant post operative pancreatic fistula
Time Frame: 10 days
|
A drainage fluid of any measurable volume with an amylase level more than three times the upper normal serum level on or after the 3rd postoperative day
|
10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mohammed A Omar, M.D., General Surgery Department, Faculty of Medicine, South Valley University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2017
Primary Completion (Actual)
July 30, 2022
Study Completion (Actual)
July 30, 2022
Study Registration Dates
First Submitted
January 8, 2023
First Submitted That Met QC Criteria
January 8, 2023
First Posted (Actual)
January 18, 2023
Study Record Updates
Last Update Posted (Actual)
July 27, 2023
Last Update Submitted That Met QC Criteria
July 25, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SVU/MED/SUR011/4/23/4/612
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.